ASCLETIS-B (01672) will report on the complete analysis of the Phase Ib study of ASC30 oral tablets at ObesityWeek in 2025, as well as the Phase Ib study of ASC30 injection, and preclinical studies on the combination therapy of ASC31 and ASC47.

ASCLETIS-B(01672) announced that it will present multiple reports in poster form at the 2025 ObesityWeek held in Atlanta, Georgia, including a comprehensive analysis of the ASC30 once-daily oral tablet Phase Ib study, the ASC30 once-monthly injection Phase Ib study, and the preclinical study of ASC31 in combination with ASC47. "These reports highlight the exciting efficacy and safety features of ASCLETIS's small molecules and peptides in the diverse obesity pipeline, while also confirming the company's proprietary technology based on structure-assisted AI drug discovery (AISBDD) and ultra-long-acting drug development platform (ULAP)," said Dr. Jinzi Wu, founder, Chairman of the Board, and CEO of ASCLETIS. "As we continue to advance the clinical development of ASC30, ASC31, and ASC47, we maintain a focus on close consultation with strategic partners to ensure ASCLETIS better meets the treatment needs of global obesity patients."